Treatment with recombinant human lysosomal β-hexosaminidase reduces GM2 accumulation in Tay-Sachs disease cells
Orhan Kerim İnci(Izmir Institute of Technology), Volkan Seyrantepe(Izmir Institute of Technology), Diego A. Súarez(Pontificia Universidad Javeriana), Nurselin Ateş(Izmir Institute of Technology), Andres F. Leal, Ángela J. Espejo(Pontificia Universidad Javeriana), Carlos Javier Alméciga-Díaz(Pontificia Universidad Javeriana)
Cited by 0
Related Papers
Neu4, a Novel Human Lysosomal Lumen Sialidase, Confers Normal Phenotype to Sialidosis and Galactosialidosis Cells
|Journal of Biological Chemistry|2004|145
Regulation of Phagocytosis in Macrophages by Neuraminidase 1
|Journal of Biological Chemistry|2009|96
Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease
|Experimental Neurology|2017|82
GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease
|Journal of Neuroinflammation|2020|65
Gangliosides as Therapeutic Targets for Neurodegenerative Diseases
|Journal of Lipids|2024|11